Von Hippel-Lindau Syndrome Surveillance Risk Calculator

Estimate penetrance and screening interval for VHL gene mutation carriers across CNS haemangioblastomas, clear cell RCC, phaeochromocytoma, pancreatic NETs, and retinal angiomas based on VHL mutation type (type 1, 2A, 2B, 2C).

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Estimate penetrance and screening interval for VHL gene mutation carriers across CNS haemangioblastomas, clear cell RCC, phaeochromocytoma, pancreatic NETs, and retinal angiomas based on VHL mutation type (type 1, 2A, 2B, 2C)

Each component has a specific meaning:

  • CNS haemangioblastomas — The cns haemangioblastomas recorded for the scenario being assessed.
  • Clear cell RCC — The clear cell rcc recorded for the scenario being assessed.
  • Phaeochromocytoma — The phaeochromocytoma recorded for the scenario being assessed.
  • Pancreatic NETs — The pancreatic nets recorded for the scenario being assessed.
  • Retinal angiomas based on VHL mutation type (type 1 — The retinal angiomas based on vhl mutation type (type 1 recorded for the scenario being assessed.
  • 2A — The 2a recorded for the scenario being assessed.

Note: Interpret the vhl risk score result against the thresholds and context described above.

How to Use

Enter the CNS haemangioblastomas, clear cell RCC, phaeochromocytoma, pancreatic NETs, retinal angiomas based on VHL mutation type (type 1, 2A for the scenario you are assessing. Estimate penetrance and screening interval for VHL gene mutation carriers across CNS haemangioblastomas, clear cell RCC, phaeochromocytoma, pancreatic NETs, and retinal angiomas based on VHL mutation type (type 1, 2A, 2B, 2C). Use the vhl risk score result to inform your calculation.

Related Calculators

BMI Calculator

Medical

Frequently Asked Questions